RenovoRx, Inc. (RNXT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US75989R1077
RenovoRx, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 1.12 m USD |
| Gross profit | 796,000.00 USD |
| Operating income | -12.51 m USD |
| EBIT | -11.17 m USD |
| Net income | -11.17 m USD |
| Diluted EPS – continuing operations | -0.32 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About RenovoRx, Inc.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
More stocks
- XIIlab Co. Ltd. (189330.KQ)
- Marpai, Inc. (MRAI)
- Sibek AB (publ) (SIBEK.ST)
- Mospec Semiconductor Corp (2434.TW)
- ONCOLYTICS BIOTECH INC (ONCY)
- Charlotte's Web Holdings, Inc. (CWBHF)
- Berkah Prima Perkasa Tbk PT (BLUE.JK)
- Daekyo (019680.KS)
- Cryomax Cooling System Corp (1587.TW)
- Air Water Ventures Limited Ordinary Shares (WATR)
- Klevo Rewards Limited (KLV.AX)
- EUDA Health Holdings Ltd (EUDA)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.